soul semaglutide Trial (NEJM 2025): Oral led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine ADA 2025: Oral Semaglutide Demonstrates

Zudem ist eine ausreichende Eiweisszufuhr wichtig, um die Muskelmasse zu erhalten

Abrupt discontinuation can trigger appetite rebound within days

Medicare GLP-1 Bridge details from cms.gov

Millions of Americans take levothyroxine for hypothyroidism, and many are also candidates for GLP-1 weight loss therapy

Phase 3 clinical trials into survodutide, a new GLP-1, showed it has the potential to combat NASH, one of the complications of NAFLD, with significant improvements seen in 83.0% of patients

A separate randomized, double-blind, placebo-controlled trial published in Nutrients found that five weeks of L-Carnitine tartrate supplementation may support recovery, reduce perceived soreness, and help blunt declines in strength and power following intense exercise challenges